Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older with stage I or II marginal zone lymphoma (including cases where the pathology report indicates "low grade B cell lymphoma, favour marginal zone lymphoma").
- People whose treatment plan does not include any systemic therapy (such as chemotherapy or immunotherapy) before the first check-up after radiation.
- People who have had prior treatment with another method (such as systemic therapy) before radiation, as long as there is still measurable disease visible on scans or physical exam before enrolling.
- People who have had prior systemic therapy, antibiotics (used to treat marginal zone lymphoma), or topical treatments (such as steroid creams for skin lymphoma), as long as those treatments were completed before the most recent disease assessment.
- People with gastric MALT lymphoma (a type of stomach lymphoma) who have had testing for a bacteria called H. pylori on their most recent tissue sample.
- Women who could become pregnant must have a negative pregnancy test within one week before radiation starts, or have documented that they declined the test.
- Women who could become pregnant and male participants must agree to use an approved form of contraception during the study period (and for men, for four months after radiation ends).
- People who are able to understand the study and are willing to sign a written consent form.
- People with large tumours (greater than 7.5 cm) may still be eligible.
- People with a previous or current different cancer, where that cancer or its treatment is unlikely to interfere with the safety or results of this trial.
Who may not be able to join:
- People under 18 years of age.
- People diagnosed with a different type of lymphoma (for example, follicular grade I/II or CLL/SLL), rather than marginal zone lymphoma.
- People who are pregnant.
- People with a psychiatric illness or personal circumstances that would make it difficult to follow the study requirements.
- People who have previously had radiation to the same area being treated, if giving more radiation would exceed safe limits for nearby organs (such as the stomach, bowel, or spinal cord).
- People who currently have active scleroderma (an autoimmune condition affecting connective tissue) that is being treated, as prior research has shown this group may experience serious side effects from radiation.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jillian Gunther, MD, M.D. Anderson Cancer Center
Phone: (832) 710-7864
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.